A successful challenge in a patient with vancomycin-induced linear IgA dermatosis.
BACKGROUND
Linear IgA bullous dermatosis (LABD), a subepidermal, blistering skin disease, is generally believed to be idiopathic. It has been reported in association with multiple medications, including vancomycin. In each case, complete clearance of the skin lesions occurred with discontinued use of the drug. A subsequent rechallenge reproduced the eruption within hours to days.


OBJECTIVE
To present a patient with vancomycin-associated LABD who underwent a successful challenge with the antibiotic 4 years after the initial reaction.


METHODS
The patient developed blistering lesions over her trunk and extremities 10 days after the initiation of vancomycin for sepsis. A biopsy specimen of a skin eruption was consistent with linear IgA dermatosis. Following discontinued use of the drug, her skin lesions resolved. Four years later, she required vancomycin for osteomyelitis.


RESULTS
The patient underwent a vancomycin-graded challenge of 5 doses over 5 days. On day 1, she received 10 mg, and this was increased in a semilog fashion to 1,000 mg on day 5. She had no recurrence of her skin lesions.


CONCLUSIONS
This is the first case, to our knowledge, to show a successful rechallenge in a patient with drug-associated LABD. Since the patient did not have a reaction to the challenge, it is possible that the IgA antibodies responsible for drug-induced LABD are only present transiently and diminish over time.
Department of Allergy-Immunology-Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA. sunil_joshi@urmc.rochester.edu
Sunil
S
Joshi
Glynis
G
Scott
R John
RJ
Looney
D001327:Autoimmune Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D008875:Middle Aged; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced*; D014640:Vancomycin / Q000009:adverse effects*
D007070:Immunoglobulin A; D014640:Vancomycin